Despite therapeutic advances, persistent inflammatory activity, evidenced by elevated CRP, continues to contribute to vascular dysfunction and increased CV risk, underscoring the need for targeted strategies that address both joint and vascular inflammation in RA management. This evidence concerns the gene CRP and rheumatoid arthritis.